Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Interventional × AM0010 × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Cisplatin 617 Carboplatin 512 Paclitaxel 495 Cyclophosphamide 455 Radiotherapy 454 Docetaxel 414 Fluorouracil 385 Gemcitabine 368 Doxorubicin 344 Capecitabine 319 Dexamethasone 285 Oxaliplatin 250 Vincristine 237 Leucovorin 237 pembrolizumab 236 Etoposide 233 Bevacizumab 228 Rituximab 209 Prednisone 201 Pemetrexed 182 Cytarabine 181 Drug Therapy 173 Methotrexate 153 Trastuzumab 149 Irinotecan 141 Lenalidomide 123 Filgrastim 120 Nivolumab 113 Chemotherapy, Adjuvant 111 Tamoxifen 108

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02923921 2020-10-19

Sequoia

Eli Lilly and Company

Phase 3 Completed

567 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡